RT Journal Article
SR Electronic
T1 Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20103549
DO 10.1101/2020.05.15.20103549
A1 Wilson, Jennifer G.
A1 Simpson, Laura J.
A1 Ferreira, Anne-Maud
A1 Rustagi, Arjun
A1 Roque, Jonasel
A1 Asuni, Adijat
A1 Ranganath, Thanmayi
A1 Grant, Philip M.
A1 Subramanian, Aruna
A1 Rosenberg-Hasson, Yael
A1 Maecker, Holden T.
A1 Holmes, Susan P.
A1 Levitt, Joseph E.
A1 Blish, Catherine A.
A1 Rogers, Angela J.
YR 2020
UL http://medrxiv.org/content/early/2020/05/16/2020.05.15.20103549.abstract
AB Rationale Elevated levels of inflammatory cytokines have been associated with poor outcomes among COVID–19 patients. It is unknown, however, how these levels compare to those observed in critically ill patients with ARDS or sepsis due to other causes.Objectives To directly compare plasma levels of inflammatory cytokines, with a focus on 6 cytokines associated with cytokine storm (IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα), between hospitalized COVID-19 patients and banked plasma samples from ARDS and sepsis patients from prior to the COVID-19 pandemic.Findings 15 hospitalized COVID-19 patients, 9 of whom were critically ill, were compared to 28 critically ill patients with ARDS or sepsis. There were no statistically significant differences in baseline levels of IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα between patients with severe COVID-19 and critically ill controls with ARDS or sepsis.Conclusions Levels of inflammatory cytokines IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα were not higher in critically ill COVID-19 patients than in critically ill patients admitted with ARDS or sepsis due to other causes in this small cohort. Broad use of immunosuppressive therapies in ARDS has failed in numerous Phase 3 studies; use of these therapies in unselected patients with COVID-19 is likely unwarranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Stanford ICU Biobank is funded by Dr. Rogers’ NHLBI K23 HL125663. C.A.B. is supported by the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Diseases #1016687, NIH/NIAID U19AI057229-16 (PI MM Davis), and is the Tashia and John Morgridge Faculty Scholar in Pediatric Translational Medicine from the Stanford Maternal Child Health Research Institute and an Investigator of the Chan Zuckerberg Biohub.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be made available at ImmPort (immport.org) upon publication of this manuscript in a peer-reviewed journal.